Why Momenta Pharmaceuticals Shares Made a Late-Day Jump Higher
August 24, 2016 at 16:49 PM EDT
A patent review board rules that claims on Teva Pharmaceuticals' three-times-weekly version of Copaxone aren't patentable.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.